Concerns following the rapid implementation of first-line screening for aneuploidies by cell-free DNA analysis in the Belgian health care system

Chris Abousleiman, Aurore Lismonde, Jacques C Jani
Ultrasound in Obstetrics & Gynecology 2019 April 2
The high performance of cell-free DNA (cfDNA) analysis of maternal blood in screening for trisomies 21, 18 and 13 in high- and low-risk pregnancies in now well established.1 In May 2017, our Minister of Public Health announced the reimbursement of non-invasive prenatal testing (NIPT) as a first-line screening tool for all pregnant women in Belgium. Patients have to pay 8.68 € out of their pocket. The decision took effect on the 1st of July 2017. Prior to the above announcement, the National Advisory Committee on Bioethics was asked to give its opinion on ethical issues that NIPT could raise, notably in matters of informed consent and patient counseling. This article is protected by copyright. All rights reserved.

Full Text Links

Find Full Text Links for this Article


You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Available on the App Store

Available on the Play Store
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"